We congratulate our portfolio team, NephroDI Therapeutics, on their recent milestone! NephroDI Therapeutics has announced a significant Series A investment by Sound Bioventures to accelerate the development of NDI-5001, a groundbreaking potential first-in-class therapy for pediatric orphan kidney disease.

This new funding will be instrumental in taking NDI-5001 into and through clinical proof of concept in treating Congenital Nephrogenic Diabetes Insipidus (NDI). This devastating genetic condition affects individuals from birth, leading to life-altering challenges such as producing large volumes of dilute urine daily and requiring excessive water intake to prevent dehydration.

With this investment and a previously announced strategic corporate partnership, NephroDI is poised to advance NDI-5001, a proprietary small molecule AMPK activator, into the clinic later this year. NDI-5001 has already received Orphan Drug Designation and Rare Pediatric Disease designation, making it eligible for the Priority Review Voucher by the FDA’s Office of Orphan Products Development.

Learn more and read the full press release at https://nephrodi.com/news/.